ArticleFrontiers in endocrinology2024
Interactive effect of phenylalanine with duration of diabetes on the risk of small vessel disease in Chinese patients with T2DM.
Article in Frontiers in endocrinology, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
2 citing papers in PubMed.
- Phenylalanine homeostasis in metabolic disorders: epidemiological trends, pathophysiological mechanisms, and clinical treatment.Frontiers in endocrinology · 2026Review
- Structural characterization and protective effects of polysaccharides isolated fromFrontiers in nutrition · 2025Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Aims: Few prior studies have explored the relationship between phenylalanine and diabetic small vessel disease (SVD) in patients with different durations of type 2 diabetes mellitus(T2DM). Our study aimed to explore whether phenylalanine is associated with the risk of SVD and to further explore whether phenylalanine interacted with the duration of T2DM to alter the risk of SVD. Materials and methods: A total of 1,032 T2DM patients were enrolled using the Liaoning Medical University First Affiliated Hospital (LMUFAH) system. SVD was defined as patients with diabetic nephropathy (DN) or diabetic retinopathy (DR) alone, or both. Serum amino acids were measured by mass spectrometry (MS) technology. A binary logistic regression model was used to examine associations of phenylalanine with SVD risk. Restricted cubic spline (RCS) regression was used to draw the odds ratio curves of plasma phenylalanine for SVD. Additive interaction analysis was employed to test the interaction of low phenylalanine with a long duration of T2DM for SVD. Results: Among the 1,032 T2DM patients, 286 (27.7%) had SVD. Phenylalanine <42μmol/L was associated with a markedly increased risk of SVD (OR 1.76, 95%CI 1.23 to 2.51), which was enhanced by a duration of T2DM of ≥5 years to 4.83 (95%CI 2.97-7.87) with significant additive interactions. The inclusion of phenylalanine and duration of T2DM into a traditional risk factor model substantially increased the area under the receiver operating characteristic curve from 0.67 to 0.71 (95% CI 0.70 to 0.75) (P <0.05). Conclusions: In Chinese patients with T2DM, phenylalanine <42μmol/L was associated with an increased risk of SVD, which was further amplified by a duration of T2DM of ≥5 years.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.